Created: 11/23/2013 8:19 AM WDIO.com
WASHINGTON (AP) — U.S. regulators have approved a new drug from Johnson & Johnson for use in treating chronic hepatitis C infections.
The Food and Drug Administration said Friday it approved the drug, a protease inhibitor that blocks a protein needed by the virus to replicate.
The Johnson & Johnson drug is designed to eliminate hepatitis C, the most common form of the liver-destroying virus. It is a daily pill taken in combination with the long-established drug cocktail used to treat the most common form of the virus.
More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that is blamed for 15,000 deaths a year.
Johnson & Johnson is one of a half-dozen companies working to develop more effective treatments for the virus as it threatens to become a major health epidemic among baby boomers and middle-age Americans.
People born between 1945 and 1965 are five times more likely to have the virus than people of other age groups. Many of them contracted the virus by sharing needles or having sex with an infected person in their youth. The disease was also spread by blood transfusions before 1992, when blood banks began testing for the virus.
For the last 20 years, the standard treatment for hepatitis C has involved a grueling one-year regimen of pills and injections. These two antiviral drugs, known as ribavirin and interferon-alpha, cause flu-like side effects including nausea, diarrhea and muscle achiness. The introduction of new drugs from Merck and Vertex Pharmaceuticals in 2011 helped shorten the treatment period and boost cure rates as high as 75 percent.
Olysio appears to be slightly more effective than the standard of care, curing 80 percent of patients who had not previously been treated for the disease, according to studies submitted to the FDA.
More significantly, the drug helped most patients cut the amount of time they had to take the traditional drug cocktail to six months.
Additionally, members of the FDA's advisory panel said the drug's once-a-day dosage should be far more manageable for patients than the current drugs from Merck and Vertex, which require taking 12 pills or six pills a day, respectively.
(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Dept. of Health Warns of E. Coli Levels at Lake Superior Beaches
With warmer temperatures, more people are hitting the water. Swimmers may still be wary of the cool water of Lake Superior, but there's something else swimmers should be aware of and you can't see it - it's E. coli.
Wisconsin's 74th Assembly Seat Debate Hits on Mining Issues
Mining was a hot issue during the debate for Wisconsin's 74th Assembly seat Wednesday night. Two democrats are vying for Rep. Janet Bewley's open seat.
Scannell Case in Jury's Hands, No Verdict Thursday
The case against Cook County Attorney Tim Scannell is now in the hands of a jury after closing arguments took place Thursday afternoon. The jury began deliberations at just after 5 p.m. and they adjourned for the night just after 8 p.m.
Wisconsin Makes Minnesota Offer on Tax Reciprocity
The neighboring states have been unable to reach a deal since a 40-year agreement expired in 2009. An agreement would simplify income taxes for the roughly 80,000 who live in one state and work in the other.
Minn. DNR Increases Target Wolf Harvest
The Minnesota DNR is increasing the target harvest for this fall's wolf hunt from 250 to 280. The DNR says the latest population survey estimates that there were 2,423 wolves living in Minnesota this past winter, which is 212 more animals than estimated the previous winter.